Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …

Epidermal growth factor receptor (EGFR) mutations are the molecular driver of a subset of
non-small cell lung cancers (NSCLC); tumors that harbor these mutations are often …

Targeted cancer therapies have produced substantial clinical responses, but most tumors
develop resistance to these drugs. Here, we describe a pharmacogenomic platform that …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) that target common non-
small-cell lung cancer mutations within the epidermal growth factor receptor (EGFR) is a …

Abstract Chromobox protein homolog 4 (CBX4) is a component of the Polycomb group
(PcG) multiprotein Polycomb repressive complexes 1 (PRC1), which is participated in …

Lung cancer is a heterogeneous genomic disease. 1 Although smoking remains the primary
cause of lung cancer, genetic susceptibility and environmental exposures are responsible …

Patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer show a
dramatic response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired drug …

Despite the recent approval of third-generation therapies, overcoming resistance to
epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small …

The development of a new generation of tyrosine kinase inhibitors (TKIs) has improved the
treatment response in lung adenocarcinomas. However, acquired resistance often occurs …

Background Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of …